Endocrinology · 2016 · 20 citations · 41 references
MedicineEndocrinologyPharmacologyMetabolic RegulationRenal PathophysiologySteroid BiochemistryDiabetes MellitusDiabetes PharmacotherapyGlycemic ControlInsulin ResistanceInsulin Signaling In MetabolismAldosterone AntagonismAldosterone SynthaseBlood Glucose RegulationGlucose-stimulated Insulin SecretionInsulin ResponseInsulin SignalingMineralocorticoid Receptor AntagonismMineralocorticoid Receptors
Plasma aldosterone is elevated in type 2 diabetes and obesity in experimental and clinical studies and can act to inhibit both glucose-stimulated insulin secretion by the β-cell and insulin signaling. Currently mineralocorticoid receptor antagonism is the best characterized treatment to ameliorate aldosterone-mediated effects. A second alternative is inhibition of aldosterone synthase, an approach with protective effects on end-organ damage in heart or kidney in animal models. The effect of aldosterone synthase inhibition on metabolic parameters in type 2 diabetes is not known. Therefore, male Zucker diabetic fatty (ZDF) rats were treated for 11 weeks with the aldosterone synthase inhibitor FAD286, beginning at 7 weeks of age. Results were compared with the mineralocorticoid receptor antagonist eplerenone. Plasma aldosterone was abolished by FAD286 and elevated more than 9-fold by eplerenone. The area under the curve calculated from an oral glucose tolerance test (OGTT) was lower and overall insulin response during OGTT was increased by FAD286. In contrast, eplerenone elevated blood glucose levels and blunted insulin secretion during the OGTT. Fasting glucose was lowered and fasting insulin was increased by FAD286 in the prediabetic state. Glycated hemoglobin was lowered by FAD286, whereas eplerenone showed no effect. We conclude that aldosterone synthase inhibition, in contrast to mineralocorticoid receptor antagonism, has the potential for beneficial effects on metabolic parameters in type 2 diabetes.
41
Robert H. Eckel, KGMM Alberti, Scott M. Grundy et al. · The Lancet · 2010 · 6.3K citations
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt, Marc A. Pfeffer, Susan F. Assmann et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text
Medicine, Cardiology, Pharmacology +16
Weight Loss and the Renin-Angiotensin-Aldosterone System
Stefan Engeli, Jana Böhnke, Kerstin Gorzelniak et al. · Hypertension · 2005 · 623 citations · Full text
Medicine, Endocrinology, Physiology +16